CClinicalTrials.gg
RecruitingNCT06095960Updated Feb 5, 2026

Telehealth Multi-Component Optional Model (MOM) Study

An interventional study of Telehealth MOM and Enhanced Standard of Care in Maternal Health, sponsored by University of Arkansas. Recruiting at 6 sites in United States. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by University of Arkansas · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
Female
01

Study summary

The aim of this study is to conduct a comparative effectiveness evaluation using a randomized control trail design among diverse women to compare two postpartum care models: 1) Telehealth Multicomponent Optimal Model (Telehealth MOM) and 2) enhanced standard of care (ESoC). This study will address critical gaps in knowledge about how best to deliver comprehensive postpartum care that ensures timely identification and treatment of complications and meets the needs and preferences of diverse patients, including disproportionately-impacted racial groups and rural residents.

02

Conditions studied

  • Maternal Health
03

In context

Lead sponsor

University of Arkansas is the lead sponsor of 391 studies on the registry; 39 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 34 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Pregnant women between 16-35 weeks gestation
  • Age 18-44 years
  • Ability to speak English, Spanish, or Marshallese
  • Participants may have either a vaginal birth or cesarean section birth

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes on an insulin pump followed closely by endocrinology
  • Uncontrolled Type 2 diabetes
  • End stage renal disease followed closely by nephrology
  • ICU admission at any point during pregnancy or delivery hospitalization
  • Other maternal conditions requiring additional surgeries (i.e. cesarean hysterectomy or intrapartum or postpartum oophorectomy/appendectomy)
  • Incarceration
  • Mental disability limiting decision-making capacity
  • Uncontrolled chronic hypertension
  • HELLP syndrome during pregnancy
  • Sickle cell disease
  • Maternal heart condition or heart disease
  • Opioid use disorder
  • Lupus
  • Thrombophilia or blood clots
  • Need for blood transfusion during delivery hospitalization
  • Other maternal conditions or complications, known during pregnancy or delivery hospitalization, requiring prolonged hospitalization postpartum
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Telehealth MOM

    Telehealth MOM. Each patient will receive ESoC which includes: education on the symptoms to watch for and when to call their healthcare provider, an in-person comprehensive postpartum visit around 6 weeks postpartum, and any additional care deemed necessary by their health care providers. Patients in the Telehealth MOM arm will be also provided with a remote monitoring blood pressure cuff and thermometer and will be instructed to take their blood pressure and temperature twice a day for 14 days after discharge from the hospital. A Registered Nurse will monitor blood pressure and temperature readings over the 14-day period and will contact the patient if the readings are out of range to discuss symptoms and the recommend a course of action. A Registered Nurse will conduct an early postpartum telehealth visit between 10-14 days postpartum.

    Behavioral: Telehealth MOM

  • Active comparator
    Enhanced Standard of Care

    Enhanced standard of care (ESoC). Each patient will be provided education on the symptoms to watch for and when to call their healthcare provider. Patients will be scheduled for a comprehensive postpartum visit around 6 weeks postpartum and any additional care deemed necessary by their health care providers.

    Other: Enhanced Standard of Care

Interventions

  • BehavioralTelehealth MOM

    Patients will receive enhanced standard of care plus remote blood pressure monitoring, remote thermometer, and a 10- to 14-day post-partum telehealth visit.

  • OtherEnhanced Standard of Care

    Patients will receive enhanced standard of care which includes: education on symptoms and when to call their healthcare provider, comprehensive 6-week post-partum visit, and any healthcare deemed necessary by providers.

06

What researchers measure

Primary outcomes

  1. Completion of post-partum 6-week comprehensive visit

    Binary measure (yes/no) of visit completion

    Time frame: Baseline to 6 weeks post-partum

07

Study locations

4 of 6 sites recruiting
  • UAMS El Dorado FMC
    El Dorado, Arkansas 71730, United States
    Not yet recruiting
  • UAMS Fayetteville FMC
    Fayetteville, Arkansas 72703, United States
    Recruiting
  • UAMS Fort Smith FMC
    Fort Smith, Arkansas 72901, United States
    Recruiting
  • UAMS Jonesboro FMC
    Jonesboro, Arkansas 72401, United States
    Not yet recruiting
  • UAMS Health Women's Center
    Little Rock, Arkansas 72205, United States
    Recruiting
  • UAMS Springdale FMC
    Springdale, Arkansas 72764, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06095960
Lead sponsor
University of Arkansas
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Feb 12, 2024
Primary completion
Jan 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Brett Rowland, MA
Contact
mbrowland@uams.edu
4797138661
Kacie Simpson, BS
Contact
klsimpson@uams.edu
4797138661
Jennifer Callaghan-Koru, PhD
principal investigator · University of Arkansas
Pearl McElfish, PhD
principal investigator · University of Arkansas

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion